Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Pharma
Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aurinia has struck a patent settlement with Teva that will likely ensure that Lupkynis will not face generic competition in the U.S. until late 2036.
Kevin Dunleavy
Aug 20, 2026 11:28am
Genentech walks the walk in lupus as sponsor of annual event
Mar 26, 2026 11:20am
FDA rejection letters flag data concerns for AZ, GSK biologics
Mar 3, 2026 11:30am
Fierce Biotech
FDA to ‘carefully shepherd’ CAR-T for autoimmune disease: Prasad
Feb 3, 2026 11:40am
FDA rejects AZ's subcutaneous version of lupus drug Saphnelo
Feb 3, 2026 9:55am
AZ touts phase 3 lupus win for subcutaneous Saphnelo
Jan 6, 2026 11:44am
